6'-allyloxy-3-(benzo[b]furan-5-yl)-2'-hydroxypropiophenone 2'-O-β-D-glucopyranoside | 217634-73-6

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 黄酮类化合物
• 英文名称: 6'-allyloxy-3-(benzo[b]furan-5-yl)-2'-hydroxypropiophenone 2'-O-β-D-glucopyranoside
• 英文别名: 6'-allyloxy-2-(benzofuran-5-yl)-2'-hydroxypropiophenone 2'-O-β-D-glucopyranoside；3-(1-benzofuran-5-yl)-1-[2-prop-2-enoxy-6-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyphenyl]propan-1-one
• CAS: 217634-73-6
• 化学式: C₂₆H₂₈O₉
• 分子量: 484.503
• InChiKey: AMQCTMWXNRIGEH-XDXGNBCUSA-N

物化性质

• 沸点：
  725.3±60.0 °C(predicted)
• 密度：
  1.367±0.06 g/cm3(Temp: 20 °C; Press: 760 Torr)(predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  35
• 可旋转键数：
  10
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.35
• 拓扑面积：
  139
• 氢给体数：
  4
• 氢受体数：
  9

反应信息

• 作为反应物：
  描述：

  6'-allyloxy-3-(benzo[b]furan-5-yl)-2'-hydroxypropiophenone 2'-O-β-D-glucopyranoside 在 2,4,6-三甲基吡啶 、 bis-triphenylphosphine-palladium(II) chloride 、 ammonium formate 作用下， 以 二氯甲烷 、 乙腈 为溶剂， 反应 6.5h， 生成 [(2R,3S,4S,5R,6S)-6-[2-[3-(1-benzofuran-5-yl)propanoyl]-3-hydroxyphenoxy]-3,4,5-trihydroxyoxan-2-yl]methyl N-phenylcarbamate
  参考文献：
  名称：

  Na+-Glucose Cotransporter Inhibitors as Antidiabetic Agents. III. Synthesis and Pharmacological Properties of 4'-Dehydroxyphlorizin Derivatives Modified at the OH Groups of the Glucose Moiety.

  摘要：

  为了克服消化道中β-葡萄糖苷酶对4'-去氢氧基根皮苷衍生物（1、2、3）的水解作用，对其葡萄糖部分上的羟基进行了多种模式的修饰，随后评估了这些修饰化合物对大鼠尿糖排泄的影响。其中，三乙酰化（9）、2,3-二乙酰化（17）、6-O-甲氧羰基化（34）、4-O-甲氧羰基化（38）和2-O-乙酰化（41）衍生物通过口服给药（p.o.）显示出比母体化合物2更强的效果。化合物34、38和41对β-葡萄糖苷酶的稳定性高于化合物2。口服活性的增加与对β-葡萄糖苷酶稳定性的增强相关。

  DOI：

  10.1248/cpb.46.1545
• 作为产物：
  描述：

  3-溴丙烯 、 2'-(β-D-glucopyranosyloxy)-6'-hydroxy-3-(5-benzo[b]-furanyl)propiophenone 在 potassium carbonate 作用下， 以 丙酮 为溶剂， 反应 5.0h， 以89%的产率得到6'-allyloxy-3-(benzo[b]furan-5-yl)-2'-hydroxypropiophenone 2'-O-β-D-glucopyranoside
  参考文献：
  名称：

  Na+-Glucose Cotransporter Inhibitors as Antidiabetic Agents. III. Synthesis and Pharmacological Properties of 4'-Dehydroxyphlorizin Derivatives Modified at the OH Groups of the Glucose Moiety.

  摘要：

  为了克服消化道中β-葡萄糖苷酶对4'-去氢氧基根皮苷衍生物（1、2、3）的水解作用，对其葡萄糖部分上的羟基进行了多种模式的修饰，随后评估了这些修饰化合物对大鼠尿糖排泄的影响。其中，三乙酰化（9）、2,3-二乙酰化（17）、6-O-甲氧羰基化（34）、4-O-甲氧羰基化（38）和2-O-乙酰化（41）衍生物通过口服给药（p.o.）显示出比母体化合物2更强的效果。化合物34、38和41对β-葡萄糖苷酶的稳定性高于化合物2。口服活性的增加与对β-葡萄糖苷酶稳定性的增强相关。

  DOI：

  10.1248/cpb.46.1545

文献信息

• Na⁺-Glucose Cotransporter (SGLT) Inhibitors as Antidiabetic Agents. 4. Synthesis and Pharmacological Properties of 4‘-Dehydroxyphlorizin Derivatives Substituted on the B Ring
  作者：Kenji Tsujihara、Mitsuya Hongu、Kunio Saito、Hiroyuki Kawanishi、Kayoko Kuriyama、Mamoru Matsumoto、Akira Oku、Kiichiro Ueta、Minoru Tsuda、Akira Saito

  DOI：10.1021/jm990175n

  日期：1999.12.1

  In our studies of Na+-glucose cotransporter (SGLT) inhibitors as antidiabetic agents, a series of novel 4'-dehydroxyphlorizin derivatives substituted on the B ring was prepared and their effects on urinary glucose excretion were evaluated in rats. Introduction of only a small alkyl group at the 4'-position increased the activity, and 3-(benzo[b]furan-5-yl)-2',6'-dihydroxy-4'-methylpropiophenone 2'-O-beta-D-glucopyranoside (4) showed the most potent effect. To overcome hydrolysis of compound 4 by beta-glucosidase in the digestive tract, the OH groups on the glucose moiety of compound 4 were modified. Three prodrugs (5, 42, and 55) were more potent than the parent compound 4 by oral administration, and finally 3-(benzo[b]furan-5-yl)-2',6'-dihydroxy-4'-methylpropiophenone 2'-O-(6-O-methoxycarbonyl-beta-D-glucopyranoside) (5) was selected as a new promising candidate. Compound 5 was metabolized mainly by liver esterase to the active form (4), which was about 10 times more potent than 5 in inhibiting SGLT. In oral glucose tolerance test in db/db mice, compound 5 dose-dependently suppressed the elevation of glucose levels. Single administration of 5 reduced hyperglycemia concurrently with increase of glucose excretion into urine in diabetic KK-A(y) mice. Furthermore, compound 5 suppressed the elevation of blood glucose levels but did not lower it below the normal level even in fasted conditions in KK-A(y) mice. Additionally, long-term treatment with 5 dose-dependently reduced hyperglycemia and HbA1c in KK-A(y) mice. These pharmacological data strongly suggest that compound 5 has a therapeutic potential in the treatment of NIDDM.
• Na+-Glucose Cotransporter Inhibitors as Antidiabetic Agents. III. Synthesis and Pharmacological Properties of 4'-Dehydroxyphlorizin Derivatives Modified at the OH Groups of the Glucose Moiety.
  作者：Mitsuya HONGU、Nobuyuki FUNAMI、Youichi TAKAHASHI、Kunio SAITO、Kenji ARAKAWA、Mamoru MATSUMOTO、Hirokazu YAMAKITA、Kenji TSUJIHARA

  DOI：10.1248/cpb.46.1545

  日期：——

  To overcome hydrolysis by β-glucosidase persent in the digestive tract, the OH groups on the glucose moiety of the 4'-dehydroxyphlorizin derivatives (1, 2, 3) were modified with various kinds of patterns, and then the effects of the modified compounds on urinary glucose excretion were evaluated in rats. Among them, triacetyl (9), , 2, 3-O-diacetyl (17), 6-O-methoxycarbonyl (34), 4-O-methoxycarbonyl (38), and 2-O-acetyl (41) derivatives showed more potent effect than the parent compound 2 by oral administration (p.o.). The stabilities of the compounds 34, 38, and 41 against β-glucosidase were higher than that of 2. The increase in oral activity was found to correlate with the enhancement of the stability against β-glucosidase.

  为了克服消化道中β-葡萄糖苷酶对4'-去氢氧基根皮苷衍生物（1、2、3）的水解作用，对其葡萄糖部分上的羟基进行了多种模式的修饰，随后评估了这些修饰化合物对大鼠尿糖排泄的影响。其中，三乙酰化（9）、2,3-二乙酰化（17）、6-O-甲氧羰基化（34）、4-O-甲氧羰基化（38）和2-O-乙酰化（41）衍生物通过口服给药（p.o.）显示出比母体化合物2更强的效果。化合物34、38和41对β-葡萄糖苷酶的稳定性高于化合物2。口服活性的增加与对β-葡萄糖苷酶稳定性的增强相关。